The USA's ChemGenex Pharmaceuticals says that the Food and Drug Administration has granted Orphan Drug designation to omacetaxine for the treatment of myelodysplastic syndromes.
MDS describes a group of bone marrow disorders that are characterized by a defect in stem cells. It is most common in elderly patients as they are more prone to bone marrow damage but it can occur in any age group. Approximately 15,000 people per year in the USA are diagnosed with MDS, making its overall annual incidence five cases per hundred thousand people.
Hagop Kantarjian, chairman of the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, said: "MDS is a very important blood disorder with significant unmet clinical needs in patients who fail approved therapies. Published data has demonstrated the clinical activity of omacetaxine in this patient population and we look forward to future possible clinical trials to consolidate our understanding of this product in the treatment of MDS."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze